Related references
Note: Only part of the references are listed.OP0177 Randomized Comparison of Triple Dmard Therapy with Methotrexate Mono-Therapy
P. H. P. De Jong et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
AB0297 Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen.
A. Batticciotto et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
AB0296 Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis
A. Nampei et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra)
J. Morel et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
OP0067 Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination with Adalimumab: Results from the Concerto Trial
G. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
OP0066 Targeting the Lowest Efficacious Dose for Rheumatoid Arthritis Patients in Remission: Clinical and Structural Impact of a Step-Down Strategy Trial Based on Progressive Spacing of TNF-Blocker Injections (Strass Trial)
B. Fautrel et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Proposal for a new nomenclature of disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Cecile Gaujoux-Viala et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis
Garifallia Sakellariou et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)
Marjatta Leirisalo-Repo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
Jacqueline Detert et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial
P. H. de Jong et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
The role of biosimilars in the treatment of rheumatic diseases
Thomas Doerner et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
ABATACEPT SC VERSUS ADALIMUMAB ON BACKGROUND METHOTREXATE IN RA: ONE YEAR RESULTS FROM THE AMPLE STUDY
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
SARILUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY
T. W. Huizinga et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
TOCILIZUMAB (TCZ) MONOTHERAPY IS SUPERIOR TO ADALIMUMAB (ADA) MONOTHERAPY IN REDUCING DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): 24-WEEK DATA FROM THE PHASE 4 ADACTA TRIAL
C. Gabay et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
Michael E. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2013)
Sonographic Joint Assessment in Rheumatoid Arthritis: Associations With Clinical Joint Assessment During a State of Remission
Miriam Gaertner et al.
ARTHRITIS AND RHEUMATISM (2013)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?
Bassel El Zorkany et al.
CLINICAL RHEUMATOLOGY (2013)
Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry
Pavel Horak et al.
CLINICAL RHEUMATOLOGY (2013)
Association Between the Initiation of Anti-Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster
Kevin L. Winthrop et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
Josef S. Smolen et al.
LANCET (2013)
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market
Ken Garber
NATURE BIOTECHNOLOGY (2013)
Therapies for Active Rheumatoid Arthritis after Methotrexate Failure
James R. O'Dell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis
Y. Hishitani et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2013)
The new 2012 German recommendations for treating rheumatoid arthritis. Differences compared to the European standpoint
J. Wollenhaupt et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2013)
Safety of Surgery After Rituximab Therapy in 133 Patients With Rheumatoid Arthritis: Data From the AutoImmunity and Rituximab Registry
S. Godot et al.
ARTHRITIS CARE & RESEARCH (2013)
Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis A Randomized Trial
Marije F. Bakker et al.
ANNALS OF INTERNAL MEDICINE (2012)
EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis
Yvonne van Eijk-Hustings et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index
Daniel Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
Charlotte L. Krieckaert et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
P. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine
Edward C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis
Monika Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Comparison of Long-Term Clinical Outcome With Etanercept Treatment and Adalimumab Treatment of Rheumatoid Arthritis With Respect to Immunogenicity
Charlotte L. Krieckaert et al.
ARTHRITIS AND RHEUMATISM (2012)
A Randomized Comparative Effectiveness Study of Oral Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis The Treatment of Early Aggressive Rheumatoid Arthritis Trial
Larry W. Moreland et al.
ARTHRITIS AND RHEUMATISM (2012)
Factors Associated With the Initiation of Disease-Modifying Antirheumatic Drugs in Newly Diagnosed Rheumatoid Arthritis: A Retrospective Claims Database Study
Machaon M. K. Bonafede et al.
CLINICAL THERAPEUTICS (2012)
Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs
Vivian P. Bykerk et al.
JOURNAL OF RHEUMATOLOGY (2012)
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
Ronald F. van Vollenhoven et al.
LANCET (2012)
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Christopher J. L. Murray et al.
LANCET (2012)
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Theo Vos et al.
LANCET (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies
Diane van der Woude et al.
RHEUMATOLOGY (2012)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study
E. van der Kooi et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study
N. B. Klarenbeek et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
P. P. Tak et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Maya H. Buch et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
Naomi B. Klarenbeek et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis
N. B. Klarenbeek et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Joint damage in rheumatoid arthritis progresses in remission according to the disease activity score in 28 joints and is driven by residual swollen joints
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2011)
Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology
Chi Chiu Mok et al.
CLINICAL RHEUMATOLOGY (2011)
Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action
Steven J. Katz et al.
CURRENT OPINION IN RHEUMATOLOGY (2011)
Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice
K. Montag et al.
INTERNAL MEDICINE JOURNAL (2011)
Hydroxychloroquine Use and Decreased Risk of Diabetes in Rheumatoid Arthritis Patients
Androniki Bili et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2011)
Etanercept Compared to Intraarticular Corticosteroid Injection in Rheumatoid Arthritis: Double-blind, Randomized Pilot Study
Christian H. Roux et al.
JOURNAL OF RHEUMATOLOGY (2011)
Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
Sarah L. Westlake et al.
RHEUMATOLOGY (2011)
Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-the early RA network (ERAN)
Patrick Kiely et al.
RHEUMATOLOGY (2011)
Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis
Helga Radner et al.
RHEUMATOLOGY (2011)
Quality Care in Seniors With New-Onset Rheumatoid Arthritis: A Canadian Perspective
Jessica Widdifield et al.
ARTHRITIS CARE & RESEARCH (2011)
Hydroxychloroquine Use Associated With Improvement in Lipid Profiles in Rheumatoid Arthritis Patients
Stephanie J. Morris et al.
ARTHRITIS CARE & RESEARCH (2011)
Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis
Rachel O'Mahony et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008
Monika Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
M. J. L. Peters et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
R. Knevel et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
S. L. Gorter et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
Monika Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
Cecile Gaujoux-Viala et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study
K. Visser et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
J. L. Nam et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Y. Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Similar Effects of Disease-Modifying Antirheumatic Drugs, Glucocorticoids, and Biologic Agents on Radiographic Progression in Rheumatoid Arthritis Meta-Analysis of 70 Randomized Placebo-Controlled or Drug-Controlled Studies, Including 112 Comparisons
Niels Graudal et al.
ARTHRITIS AND RHEUMATISM (2010)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
Use of glucocorticoids in rheumatoid arthritis - Pratical modalities of glucocorticoid therapy: Recommendations for clinical practice based on data from the literature and expert opinion
Emmanuelle Dernis et al.
JOINT BONE SPINE (2010)
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
Sarah L. Westlake et al.
RHEUMATOLOGY (2010)
Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard
Alejandro Balsa et al.
RHEUMATOLOGY (2010)
Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis
W. Katchamart et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
J. S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
K. Visser et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
C. Salliot et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Rheumatoid Arthritis Joint Progression in Sustained Remission Is Determined by Disease Activity Levels Preceding the Period of Radiographic Assessment
D. Aletaha et al.
ARTHRITIS AND RHEUMATISM (2009)
Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis
Olivier Brocq et al.
JOINT BONE SPINE (2009)
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
R. F. van Vollenhoven et al.
LANCET (2009)
Management of RA medications in pregnant patients
Monika Ostensen et al.
NATURE REVIEWS RHEUMATOLOGY (2009)
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial
Martin Soubrier et al.
RHEUMATOLOGY (2009)
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis
Nathan Vastesaeger et al.
RHEUMATOLOGY (2009)
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
D. Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?
A. Gonzalez et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
The importance of reporting disease activity states in rheumatoid arthritis clinical trials
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2008)
The burden of rheumatoid arthritis and access to treatment: health burden and costs
J. Lundkvist et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2008)
The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
G. Kobelt et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2008)
New therapies for treatment of rheumatoid arthritis
Josef S. Smolen et al.
LANCET (2007)
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
J. N. Hoes et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2007)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice:: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study
P. L. C. M. van Riel et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
P Emery et al.
ARTHRITIS AND RHEUMATISM (2006)
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
E Baecklund et al.
ARTHRITIS AND RHEUMATISM (2006)
Safety of low dose glucocorticoid treatment in rheumatoid arthritis:: published evidence and prospective trial data
JAP Da Silva et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years - A multicenter, double-blind, placebo-controlled trial
S Wassenberg et al.
ARTHRITIS AND RHEUMATISM (2005)
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate -: A two-year randomized trial
B Svensson et al.
ARTHRITIS AND RHEUMATISM (2005)
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) - A randomized, controlled trial
YPM Goekoop-Ruiterman et al.
ARTHRITIS AND RHEUMATISM (2005)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees
M Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2004)
Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review
T Pincus et al.
RHEUMATOLOGY (2002)
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens:: current questions and tentative answers in rheumatology
F Buttgereit et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
Methotrexate and mortality in patients with rheumatoid arthritis:: a prospective study
HK Choi et al.
LANCET (2002)
COBRA combination therapy in patients with early rheumatoid arthritis -: Long-term structural benefits of a brief intervention
RBM Landewé et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
